|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910438005303321 |
|
|
Titolo |
Human Fetal Tissue Transplantation / / edited by Niranjan Bhattacharya, Phillip Stubblefield |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
London : , : Springer London : , : Imprint : Springer, , 2013 |
|
|
|
|
|
|
|
ISBN |
|
1-299-33623-X |
1-4471-4171-7 |
|
|
|
|
|
|
|
|
Edizione |
[1st ed. 2013.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (466 p.) |
|
|
|
|
|
|
Altri autori (Persone) |
|
BhattacharyaNiranjan |
StubblefieldPhillip |
|
|
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Part I The ideas behind this book -- Part II Basic Science and the unique aspect of fetal growth and maturation -- Part III Fetal Cell transplant experiments in animal and human systems -- Part IV Fetal tissue transplant experiments in animal and human systems -- Part V Fetal Organ transplant experiments in animal and human systems -- Part VI Biobanking -- Ethics of fetal tissue transplant. |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
Over the past decade there have been major advances in the field of regenerative medicine with the promise to bring to reality, cures for debilitating diseases such as diabetes, heart failure, and Parkinson’s disease. Cellular products from a variety of sources are being evaluated for their ability to replace damaged tissue. Fetal tissues consist of stem cells and progenitor cells which have undergone initial commitment with varying states of differentiation. Stem cells from fetal tissues may also have a greater proliferative potential than their adult counterparts. In addition, fetal derived stem and progenitor cells are immunologically naive and some sources of fetal cells, eg cord blood, have been shown to be capable of crossing greater HLA mismatching resulting in less rejection and decreased immune mediated toxicities. Given the increasing focus on HES and advances in our basic knowledge of regenerative medicine it is an appropriate time to review the biology |
|
|
|
|